BC biologists identify alternative brain cancer treatmentFebruary 21, 2007High-fat, low-carbohydrate diet significantly slows tumor growth and enhances health in mice CHESTNUT HILL, Mass., Feb. 21 - Boston College biologists have identified an alternative, diet-based method of treating brain cancer that does not involve administering toxic chemicals, radiation or invasive surgery. The biologists found that KetoCal, a commercially available high-fat, low-carbohydrate diet designed to treat epilepsy in children, can significantly decrease the growth of brain tumors in laboratory mice. Moreover, the diet significantly enhanced health and survival rates relative to mice in control groups who consumed a standard low-fat, high-carbohydrate diet. The findings were based on a study published this week in the online journal Nutrition & Metabolism. "KetoCal represents a novel alternative therapy for malignant brain cancer," said Boston College Biology Professor Tom Seyfried, who conceived and supervised the study. "While the tumors did not vanish in the mice who received the strict KetoCal diet, they got significantly smaller and the animals lived significantly longer. And compared to radiation, chemotherapy and surgery, KetoCal is a relatively inexpensive treatment option." Malignant brain cancer is one of the most lethal types of cancer in adults and is the second leading cause of cancer death in children. Many current ways of treating the disease fail to provide long-term management because they ineffectively target tumor cells and harm the health and vitality of normal brain cells. The KetoCal diet gets around this dilemma by essentially starving the brain tumor cells of the sugary molecules on which they rely for growth and survival. Because of its special composition, the diet deprives the tumor cells of the glucose they need; at the same time, the diet provides normal brain cells with ketones, a class of organic compounds they can metabolize effectively but the tumor cells cannot. In their experiment, the BC team surgically implanted two different kinds of tumors into the brains of male mice. The mice were then divided into three groups. One group was fed a high-carbohydrate mouse chow, one was given unlimited amounts of KetoCal, and the final group was given KetoCal in a restricted dosage. The researchers found that in the mice on the restricted diet, KetoCal decreased the growth of brain tumors by between 35 percent and 65 percent. Moreover, survival rates were higher in the mice on the restricted diet. "This preclinical study indicates that KetoCal is a safe and effective diet therapy and should be considered as an alternative therapeutic option for malignant brain cancer," the researchers wrote. KetoCal is manufactured by Nutricia North America. The study authors report they have no financial interests in the company, although it did provide the KetoCal used in the experiments as a gift. The journal article's lead author is Weihua Zhou, a research technician in the Boston College Biology Department. Co-authors include Seyfried, Purna Mukherjee, Michael Kiebish, William Markis and John Mantis. Boston College |
|||||||||||||||||||||
| Related Brain Cancer Current Events and Brain Cancer News Articles Cancer metabolism discovery uncovers new role of IDH1 gene mutation in brain cancer Agios Pharmaceuticals today announced that its scientists have established, for the first time, that the mutated IDH1 gene has a novel enzyme activity consistent with a cancer-causing gene, or oncogene. Magnetic nanoparticles to simultaneously diagnose, monitor and treat Whether it's magnetic nanoparticles (mNPs) giving an army of 'therapeutically armed' white blood cells direction to invade a deadly tumour's territory, or the use of mNPs to target specific nerve channels and induce nerve-led behaviour (such as the life-dependant thumping of our hearts), mNPs have come a long way in the past decade. Angiochem crosses BBB, shows safety, efficacy in phase 1/2 brain cancer studies Angiochem, Inc. a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier to treat brain diseases, announced today that its lead drug candidate, ANG1005, has demonstrated a favorable safety and efficacy profile in more than 100 patients with brain cancer from two separate Phase 1 /2 clinical studies in patients with progressive gliomas, including recurrent glioblastoma, and in patients with progressive brain metastases. Toward a nanomedicine for brain cancer In an advance toward better treatments for the most serious form of brain cancer, scientists in Illinois are reporting development of the first nanoparticles that seek out and destroy brain cancer cells without damaging nearby healthy cells. UM scientists pinpoint critical molecule to celiac disease, possibly other autoimmune disorders It was nine years ago that University of Maryland School of Medicine researchers discovered that a mysterious human protein called zonulin played a critical role in celiac disease and other autoimmune disorders, such as multiple sclerosis and diabetes. Experts warn over health check brain scans A new study has voiced concern about the growing market for brain screening tests, which people can buy as part of a general health MOT. Avastin dramatically improves response, survival in deadly recurrrent glioblastomas The targeted therapy Avastin, alone and in combination with the chemotherapy drug CPT-11, significantly increased response rates, progression-free survival times and survival rates in patients with a deadly form of brain cancer that had recurred. Computational Process Zeroes in on Top Genetic Cancer Suspects Johns Hopkins engineers have devised innovative computer software that can sift through hundreds of genetic mutations and highlight the DNA changes that are most likely to promote cancer. NIH study reveals new genetic culprit in deadly skin cancer Drawing on the power of DNA sequencing, National Institutes of Health researchers have identified a new group of genetic mutations involved in the deadliest form of skin cancer, melanoma. NIH researchers identify key factor that stimulates brain cancer cells to spread Researchers funded by the National Institutes of Health have found that the activity of a protein in brain cells helps stimulate the spread of an aggressive brain cancer called glioblastoma multiforme (GBM). More Brain Cancer Current Events and Brain Cancer News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||